Tecovirimat monotherapy found ineffective for treating clade II mpox in NIH-sponsored trial Post author:admin Post published:March 12, 2025 Post category:uncategorized NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions. You Might Also Like Promising breakthroughs ignite hope for a novel and effective Tuberculosis vaccine October 17, 2023 Unlocking the health benefits of Valentine’s Day chocolates February 16, 2024 Cubic receives European patent for medical ultrasonic gas sensor February 13, 2025